Rion

???We're Hiring! Join Us as a Research Associate??? We’re looking for a?Research Associate?to join our?Research & Development team in Rochester, MN. This role involves hands-on lab work, including?mammalian cell culture, flow cytometry, ELISA, RT-qPCR, and more, contributing to the advancement of exosome-based therapeutics. ???If you're passionate about?biological sciences, innovation, and working in a highly collaborative environment, we encourage you to apply! ???Location:?Rochester, Minnesota ???Department:?Research & Development ???Click the link below to apply through our website! https://lnkd.in/evEf9Rui #NowHiring #Biotechnology #ResearchAssociate #RegenerativeMedicine #Exosomes #LifeSciences #Hiring #JobOpening

We are excited to announce the enrollment of the first patient in our Phase 1b clinical trial evaluating Purified Exosome Product? (PEP?) for knee osteoarthritis (OA), marking a significant milestone in the field of regenerative medicine. This trial represents a pivotal moment for both RION and the future of knee osteoarthritis treatment. ? The open-label, multi-center study will involve 24 patients across the United States, focusing on the safety, tolerability, and preliminary efficacy of PEP? for Knee OA. Participants with symptomatic unilateral Knee OA will receive single intra-articular injections of PEP? in escalating doses, aiming to evaluate its potential in promoting cartilage regeneration and reducing inflammation. ? At RION, our mission is to transform patient care through innovative exosome technology. Built on two decades of research, our proprietary PEP? platform is designed to address the unmet needs of chronic conditions like Knee OA by leveraging the body's natural repair mechanisms. ? Learn more about this groundbreaking trial and the potential of our PEP? technology by clicking the link below. https://lnkd.in/eUMvA7SA

Very excited to progress the Knee Osteoarthritis clinical trial with PEP

Atta Behfar, MD, PhD, Co-Founder of RION, had the honor of presenting at the 43rd Annual J.P. Morgan Healthcare Conference. ? This is the 2nd?year that RION has had the opportunity to share our vision for transforming regenerative medicine with our innovative exosome platform - Purified Exosome Product? (PEP? biologic).?RION was chosen amongst an exclusive group of private companies to present at the prestigious healthcare conference. ? Please reach out to Scott McCrea, MBA, SVP of BD at RION, for more information on the RION presentation

Rion Achieves Full Enrollment in Phase 2 Clinical Study for PEP? in Diabetic Foot Ulcers Rion has reached a significant milestone in regenerative medicine, announcing the full enrollment of its Phase 2 clinical trial for Purified Exosome Product? (PEP?) in treating Diabetic Foot Ulcers (DFUs). This marks a critical step toward addressing a major unmet need in chronic wound care. The multi-center study includes 59 patients across the U.S. and evaluates the safety and efficacy of PEP?, a proprietary exosome-based powder derived from human platelets, in promoting wound healing. Dr. Atta Behfar, co-founder of Rion, emphasized: "PEP? has the potential to transform diabetic wound care by addressing a significant unmet need with a novel therapeutic approach." DFUs affect over 18.6 million individuals globally each year and represent a $13 billion annual burden in the U.S. alone. Despite this, no new biologics have been approved for diabetic wound care in over two decades. PEP? leverages stabilized regenerative exosomes to enhance cellular growth, angiogenesis, and inflammation reduction, unlocking the body’s natural healing potential. With promising Phase 1B data from Mayo Clinic, RION is now advancing toward a pivotal Phase 3 study, aiming to file a Biologics License Application with the FDA. Rion’s innovative approach reflects its commitment to rewriting the regenerative medicine playbook, addressing multiple indications with its exosome-based PEP? technology. #RegenerativeMedicine #ExosomeTherapeutics #DiabeticFootUlcers #WoundCare #ClinicalTrials #InnovationInHealthcare #PEPTechnology #ChronicWoundCare #Biologics #CellTherapy #FutureOfMedicine

We are excited to be making headlines again, this time announcing the completion of patient enrollment in the Phase 2 clinical trial for Purified Exosome Product? (PEP?) in the treatment of Diabetic Foot Ulcers (DFUs). As a major complication of diabetes, DFUs affect millions of individuals globally each year, leading to significant morbidity, mortality, and financial burden. This milestone marks a pivotal step forward in our mission to develop cutting-edge therapies that address critical challenges in chronic wound care. For more information, make sure to read the official press release: https://lnkd.in/eRed_mjv

We’re excited to announce that Dr. Atta Behfar, Co-Founder of RION, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference! Don’t miss the presentation: ? Date: Thursday, January 16, 2025 ? Time: 10:00 AM PST Dr. Behfar will showcase RION’s groundbreaking Purified Exosome Product? (PEP?) technology and its potential to transform regenerative medicine by addressing unmet clinical needs with innovative and scalable solutions. We’re thrilled to share our advancements and connect with industry leaders to explore new possibilities in healthcare. For more details, read our press release: https://lnkd.in/e_vbKgSD

We’re excited to announce that Dr. Atta Behfar, Co-Founder of RION, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference! Don’t miss the presentation: ? Date: Thursday, January 16, 2025 ? Time: 10:00 AM PST Dr. Behfar will showcase RION’s groundbreaking Purified Exosome Product? (PEP?) technology and its potential to transform regenerative medicine by addressing unmet clinical needs with innovative and scalable solutions. We’re thrilled to share our advancements and connect with industry leaders to explore new possibilities in healthcare. For more details, read our press release: https://lnkd.in/e_vbKgSD

We are proud to share that RION has been invited to participate in investor 1x1s at the 43rd Annual J.P. Morgan Healthcare Conference. This invitation is a testament to RION’s role in shaping the future of healthcare innovation and an exciting opportunity to connect with top-tier investors, industry experts, and potential collaborators. These one-on-one meetings provide a platform for engaging in meaningful discussions about: ? RION’s pioneering advancements in regenerative medicine ? The transformative potential of our innovative exosome technology ? Exploring collaborations and partnerships to drive impactful innovation To schedule a meeting, please contact your J.P. Morgan representative or reach out to Scott McCrea, Sr. VP of Business Development, at [email protected]. We look forward to connecting in San Francisco!

We are proud to share that RION has been invited to participate in investor 1x1s at the 43rd Annual J.P. Morgan Healthcare Conference. This invitation is a testament to RION’s role in shaping the future of healthcare innovation and an exciting opportunity to connect with top-tier investors, industry experts, and potential collaborators. These one-on-one meetings provide a platform for engaging in meaningful discussions about: ? RION’s pioneering advancements in regenerative medicine ? The transformative potential of our innovative exosome technology ? Exploring collaborations and partnerships to drive impactful innovation To schedule a meeting, please contact your J.P. Morgan representative or reach out to Scott McCrea, Sr. VP of Business Development, at [email protected]. We look forward to connecting in San Francisco!